期刊
CLINICAL CANCER RESEARCH
卷 28, 期 14, 页码 3104-3115出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-21-4531
关键词
-
类别
资金
- Wellcome Trust
- Prostate Cancer Foundation
- NIHR Biomedical Research Centre
- Prostate Cancer UK
- Movember Foundation through the London Movember Centre of Excellence [CEO13_2-002]
- Cancer Research UK
- Experimental Cancer Medicine Centre
- Biomedical Research Centre
- Institute of Cancer Research
- Department of Health
- Prostate Cancer UK Travelling Prize Fellowship
This study found that anticancer treatment-induced double-strand DNA damage can upregulate PSMA protein expression, providing support for exploring rational combinations to maximize the antitumor activity of PSMA-targeted therapeutic strategies by upregulating PSMA.
Purpose: Prostate-specific membrane antigen (PSMA) tar-geting therapies such as Lutetium-177 (177Lu)-PSMA-617 are affecting outcomes from metastatic castration-resistant pros-tate cancer (mCRPC). However, a significant subset of patients have prostate cancer cells lacking PSMA expression, raising concerns about treatment resistance attributable at least in part to heterogeneous PSMA expression. We have previously demonstrated an association between high PSMA expression and DNA damage repair defects in mCRPC biopsies and therefore hypothesized that DNA damage upregulates PSMA expression. Experimental Design: To test this relationship between PSMA and DNA damage we conducted a screen of 147 anticancer agents (NCI/NIH FDA-approved anticancer Oncology Set ) and treated tumor cells with repeated ionizing irradiation. Results: The topoisomerase-2 inhibitors, daunorubicin and mitoxantrone, were identified from the screen to upregulate PSMA protein expression in castration-resistant LNCaP95 cells; this result was validated in vitro in LNCaP, LNCaP95, and 22Rv1 cell lines and in vivo using an mCRPC patient-derived xenograft model CP286 identified to have heterogeneous PSMA expression. As double-strand DNA break induction by topoisomerase-2 inhibitors upregulated PSMA, we next studied the impact of ionizing radiation on PSMA expression; this also upregulated PSMA protein expression in a dose-dependent fashion. Conclusions: The results presented herein are the first, to our knowledge, to demonstrate that PSMA is upregulated in response to double-strand DNA damage by anticancer treatment. These data support the study of rational combinations that maximize the antitumor activity of PSMA-targeted therapeutic strategies by upregulating PSMA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据